Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q3 2023 (← Previous) (Next →)

Filing Date: Nov 3, 2023

Total Value ($000): $188,112 (100.0% shares, 0.0% debt)

Holdings (8)

— RayzeBio, Inc. 60.9%

Value ($000) $114,511 Shares 5,158,161 Est. Cost $22.20 Unrealized —

— Repare Therapeutics, Inc. 17.0%

Value ($000) $31,972 Shares 2,646,657 Est. Cost $10.58 Unrealized —

CRSP CRISPR Therapeutics AG 12.0%

Value ($000) $22,630 Shares 498,558 Est. Cost $40.26 Unrealized +28.3%

— Adverum Biotechnologies, Inc. 4.0%

Value ($000) $7,602 Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Gritstone Oncology, Inc. 3.3%

Value ($000) $6,125 Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Passage Bio, Inc. 1.7%

Value ($000) $3,264 Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Aligos Therapeutics, Inc. 0.9%

Value ($000) $1,733 Shares 2,320,381 Est. Cost $27.65 Unrealized —

— Minerva Surgical Inc. 0.1%

Value ($000) $275 Shares 83,684 Est. Cost $5.14 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	RayzeBio, Inc.	5,158,161	$114,511	60.9%	$22.20	—	Common Stock	75525N107
—	Repare Therapeutics, Inc.	2,646,657	$31,972	17.0%	$10.58	—	Common Stock	760273102
CRSP	CRISPR Therapeutics AG	498,558	$22,630	12.0%	$40.26	+28.3%	Common Shares	H17182108
—	Adverum Biotechnologies, Inc.	5,068,233	$7,602	4.0%	$9646.10	—	Common Stock	00773U108
—	Gritstone Oncology, Inc.	3,561,150	$6,125	3.3%	$7767.86	—	Common Stock	39868T105
—	Passage Bio, Inc.	4,959,769	$3,264	1.7%	$17.48	—	Common Stock	702712100
—	Aligos Therapeutics, Inc.	2,320,381	$1,733	0.9%	$27.65	—	Common Stock	01626L105
—	Minerva Surgical Inc.	83,684	$275	0.1%	$5.14	—	Common Stock	60343F106